UTHR
United Therapeutics Corporation
NASDAQ · Healthcare · Biotechnology · US
$487.61
−0.54%Sep 2, 2026, 11:00 UTC
United Therapeutics announced that the FDA accepted its supplemental New Drug Application for nebulized Tyvaso (treprostinil) Inhalation Solution to treat idiopathic pulmonary fibrosis, with review expected to complete in late April 2027.
Source:Aug 24, 2026, 11:00 UTC
United Therapeutics Corporation announced that the FDA has accepted its New Drug Application for ralinepag to treat pulmonary arterial hypertension, with a target action date of June 24, 2027.
Aug 18, 2026, 15:41 UTC
United Therapeutics completed enrollment in its Phase III study evaluating Tyvaso for an additional indication, progressive pulmonary fibrosis (PPF), with top-line results expected in the second half of 2027.
Source:Aug 11, 2026, 08:09 UTC
United Therapeutics CEO Martine Rothblatt sold 9,500 shares of the company's stock on August 7, 2026, at an average price of $531.38, totaling about $5.05 million.
Source:Aug 5, 2026, 10:30 UTC
United Therapeutics Corporation reported its financial results for the second quarter of 2026, with total revenues decreasing by two percent year-over-year to $783.3 million from $798.6 million in the same quarter of 2025.
Jul 29, 2026, 10:30 UTC
United Therapeutics Corporation announced that The Lancet published full results of its ADVANCE OUTCOMES study of ralinepag for pulmonary arterial hypertension.
Source:Jul 23, 2026, 00:00 UTC
United Therapeutics Corp appointed Victor Dzau, M.D. as a member of its Board of Directors, effective July 22, 2026.
Jul 2, 2026, 10:30 UTC
United Therapeutics Corporation acquired Thymmune Therapeutics, Inc.
Jun 29, 2026, 10:30 UTC
The U.S. Food and Drug Administration granted premarket approval of the LungFX device for centralized ex vivo lung perfusion, submitted by United Therapeutics Corporation.
Source: